Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Atrial Fibrillation Recurrent
- Catheter Ablation
- Pulmonary Venous Isolation
- Sodium-glucose Co-transporter 2 Inhibitors
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04780438
- Collaborators
- 2nd Department of Cardiology, "Attikon" University Hospital, National and Kapodistrian University of Athens
- Investigators
- Principal Investigator: Spyridon Deftereos, MD 2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece